Saturday, October 31, 2026

THE CEO CRIES FOUL: NVIDIA’s Jensen Huang Says US Is SO BLIND To China’s ‘Free Electricity’ AI Advantage

Jensen Huang warns that China may surpass the U.S. in AI due to lower energy costs and better regulations, urging optimism in the West.

LG Electronics Collects Over 100 Tons of Waste Batteries in Four-Year Campaign

LG Electronics has collected over 1 million tons of waste batteries, expanding its Battery Return campaign to recycle rare metals and engage customers.

South Korea Enhances COVID Defense with New Vaccine Tailored to JN.1 Variant

The Korea Disease Control and Prevention Agency...

News1

Author's Latest

Cenobamate Reduces Seizures in Real-World Epilepsy Care, With Quality-of-Life Benefits Also Emerging

Real-world studies show that cenobamate reduced seizure frequency in adults with drug-resistant epilepsy, while also highlighting potential improvements in quality of life and cognitive function.

Robot-Assisted Bilateral Spinal Endoscopy: Hallym University Gangnam Sacred Heart Hospital Opens Training Center

Hallym University Gangnam Sacred Heart Hospital has opened a training center that combines bilateral spinal endoscopy with robotic and navigation technology to train physicians in Korea and abroad.

Angel Robotics Unveils Wearable Robot for Physical AI Research

Angel Robotics has introduced phai-x1, a wearable robot platform designed to collect human movement data and enable researchers to test their own physical AI control algorithms.

Pharos iBio Expands Open Innovation in Australia, Strengthening AI Drug Development Partnerships

Pharos iBio is using its Australian operations as a hub to expand global open-innovation partnerships in AI-driven drug development.

Celltrion to Expand Global Supply Chain and CDMO Partnerships at CPHI, Accelerating Push to Become Global Drugmaker

Celltrion will use its participation in CPHI 2026 to expand partnerships in novel drugs, manufacturing and contract development and manufacturing while strengthening its global supply capabilities.

“Focus on What We Do Well”: Kim Yeol-hong’s Vision for Yoo Han Corp.’s Next 100 Years

Yoo Han Corp. R&D chief Kim Yeol-hong says the company’s next century should be built around repeatedly developing new drugs by deepening expertise in selected fields, adopting new technologies and attracting global talent.

Yoo Han Corp. R&D Chief Kim Yeol-hong: “We Expect a Second Lexraza This Year … and Will Expand Drug Development”

Yoo Han Corp. R&D chief Kim Yeol-hong said the company expects follow-up drug development results by year-end while continuing to build a broad pipeline through both internal research and external acquisitions.

How Seoul Asan Hospital’s New Fetal Heart Center is Revolutionizing Care for High-Risk Pregnancies

A 35-year-old woman named Park, who conceived through IVF, underwent a detailed fetal heart ultrasound at 21 weeks in Mokpo, Jeonnam.

How Lunit’s AI is Transforming Breast Cancer Screening in Stockholm: A Game Changer for 2026

Lunit announces the nationwide implementation of its AI imaging solution Lunit Insight MMG for breast cancer screening in Sweden.

How Elevated IgA Levels Contribute to Alcohol-Related Liver Disease: New Insights from Recent Research

Research reveals that Immunoglobulin A (IgA), known as the guardian antibody, may drive liver inflammation in alcohol-related liver disease.

Onconic Therapeutics Unveils Promising New Drug Candidate Ahead of ObesityWeek 2026

Onconic Therapeutics announced its new drug candidate's first research results will be presented at ObesityWeek 2026 in Washington D.C.

SOT106: The Breakthrough ADC for Osteosarcoma and Soft Tissue Sarcoma Secures FDA Fast Track Status

LigaChem Biosciences' ADC platform SOT106 gains rare disease and fast track designations in the U.S., accelerating clinical entry for sarcomas.

Qurient Expands Dual Payload ADC Technology: What This Means for Cancer Treatment in 2026

Qurient expands its platform for Dual Payload antibody-drug conjugate technology, combining two types of anticancer agents in one antibody.

Samsung Biologics Redefines Biopharmaceuticals: 3.5-Month Development Time Reduction Revealed at BPI 2026

Samsung Biologics reveals process innovations that cut biopharmaceutical development time by 3.5 months and double cell culture productivity.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.